These results demonstrate that a novel Quatramer encapsulation of a PI3‐Kδ/HDAC6 dual inhibitor (HSB‐510) represents an approach for the successful targeting of breast cancer and potentially other cancer types. The gene discussed is HDAC6; the disease is breast carcinoma.